An observational study in Atherosclerosis, sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III. Active, not recruiting at 1 site in Spain. Open to participants aged 40 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-29.
Sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Atherosclerosis with a site in Spain — 10 open to participants now, 25 under way, 12 of them phase 3. Atherosclerosis · Spain.
Among the 61 studies in Atherosclerosis with a site in Spain, this one is the 5th largest by enrollment of the 20 observational ones that give a count, is the only one that started in 2010, is one of 20 observational ones, reaches primary completion later than 21 of the 24 other live ones, and was the 13th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →10 of the 61 studies in Atherosclerosis with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, United States, Australia and 4 more countries
Ages 45–80
Instituto de Investigación Hospital Universitario La Paz · Sites in Spain
Ages 50+
Instituto de Investigación Marqués de Valdecilla · Sites in Spain
Ages 50+
Eli Lilly and Company · Sites in Spain, United States, Argentina and 25 more countries
Ages 18+
Instituto de Investigación Biomédica de Salamanca · Sites in Spain, France, Netherlands
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 40 Years to 54 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 20 · Phase 4 3
First in 2004; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,184 is above the median of 250 across 526 observational studies indexed under Atherosclerosis.
Median enrollment 969 across the 41 interventional studies, 255 across the 20 observational. Of the 31 that completed or were terminated, 12 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 61 have an industry lead sponsor. The 10 most frequent:
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III has 2 studies filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Atherosclerosis with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05202509Phase 3NewAmsterdam PharmaCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | 2026-11 |
| NCT07000123Phase 3AstraZenecaA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | 2027-01-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06977295Instituto de Investigación Biomédica de SalamancaEvaluation of a Diagnostic Software for Coronary Artery Disease Using Retrospective CCTA Data (CODEX-1 Study) | 2026-11-30 |
| NCT06958315Novartis PharmaceuticalsInclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study | 2027-05-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 61 studies in Atherosclerosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall objective of this study is to characterize the prevalence and progression rate of subclinical atherosclerotic lesions and to study their association to the imaging characteristics of atheroma plaques and to the presence of genetic, epigenetic, metabolomic, and environmental factors, including dietary habits, physical activity, biorhythms, psychosocial characteristics, and exposure to environmental pollutants
Atherosclerosis is the most common cardiovascular disease and accounts for the greatest number of deaths. Atherosclerotic disease starts at an early age and follows a subclinical course for decades, becoming apparent in the fifth or sixth decades of life in men and approximately 10 years later in women. Its main clinical signs include myocardial infarction, angina pectoris, sudden death, or stroke. Disease occurrence and progression are conditioned by the presence of the so-called risk factors: smoking, dyslipidemia, hypertension, and diabetes, among others. From these factors, a number of equations have been developed for predicting the risk of an individual to suffer the disease, in order to apply adequate prevention measures such as lifestyle changes or drug treatment. However, despite the proven efficacy of such interventions, cardiovascular prevention has many limitations due to three significant problems:
Technological advances made in the past decade in both laboratory tests and medical imaging have opened up new expectations for detection and treatment of atherosclerotic disease. Current research is focused on two aspects:
Very few population studies making combined use of some of these procedures are available. The actual potential of this approach and the impact it may have on early diagnosis of subclinical atherosclerosis, its progression, and its relationship to risk factors have not been assessed to date.
The target population of the study consists of employees (N= 4,184) of the Banco de Santander Group in the Madrid region (65% males and 35% females, aged 40-54 years).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with the following conditions will also be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To assess the prevalence and 6-year progression rate of subclinical atherosclerotic disease in a population aged 40-54 years using basic and advanced cardiovascular imaging techniques.
The basic imaging tests consist of vascular 2D and 3D ultrasound in carotid, aorta and ilio-femoral arteries and computed tomography (CT) for coronary artery calcification. The advanced imaging test consist of magnetic resonance imaging (MRI) and 18F-fluorodeoxyglucose-positron emission tomography (18FDG PET) in carotid and ilio-femoral territories. These imaging techniques enable early detection of subclinical atherosclerosis, characterization of the atherosclerotic burden, and monitoring of disease progression.
Time frame: 20 years
To assess the association of both emerging and traditional cardiovascular risk factors with progression of subclinical atherosclerotic disease.
The main emerging risk factors to be investigated will be genetic markers (using genome-wide association scans), epigenetic markers (by genome-wide analysis of DNA methylation), and metabolomic markers (metabolomic profile in serum). Conventional factors are defined as those included in the prediction equations (European SCORE equation for Mediterranean countries and REGICOR), dietary habits, physical activity, and psychosocial characteristics.
Time frame: 20 years
To characterize the composition and evolution of atherosclerotic lesions using MRI and 18FDG PET to determine their relationship to risk factors and genetic, epigenetic, metabolomic, and environmental factors.
Time frame: 20 years
To assess the prevalence and progression of subclinical atherosclerosis in perimenopausal women and its relationship to cardiovascular risk factors and hormonal changes.
Time frame: 20 years
Plan to share: Undecided
Started Jun 2010 (actual). Primary completion is estimated for Jun 2030, 240 months after the start.
Of 145 non-industry observational studies under Atherosclerosis, half reached primary completion within 84 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 158. This study's planned 240 months is above that.
Counting every sponsor, half of 170 studies reached it within 62 months; a quarter within 31 and three quarters within 153.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III